Market revenue in 2023 | USD 133.2 million |
Market revenue in 2030 | USD 764.8 million |
Growth rate | 28.4% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.22% in 2023. Horizon Databook has segmented the Australia cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Australia is considered to have one of the best healthcare systems in the world. The increasing awareness about the need for early detection of lifestyle and the rising prevalence of chronic diseases are expected to boost the market in the country.
Moreover, the Australian government initiated numerous schemes to provide medicines at subsidized rates. For instance, as per the Pharmaceutical Benefits Scheme (PBS), medicines are available for all eligible patients at a subsidized cost.
These factors are expected to improve & promote the demand for pharmaceutical manufacturing, boosting the demand for cell & gene therapy CDMO services in the country. Furthermore, the adoption of advanced manufacturing technologies and processes can enhance efficiency, reduce costs, and improve the overall quality of cell & gene therapy CDMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Australia cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account